DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-687/S-015

Merck & Co., Inc., Agent for
MSP Singapore Company, LLC
Attention: Vijay K. Tammara, Ph.D.
Director, Regulatory Affairs
Sumneytown Pike, P.O. Box 104, BLA-20
West Point, PA 19486

Dear Dr. Tammara:

Please refer to your supplemental new drug application, dated April 26, 2006, received April 27, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vytorin (ezetimibe/simvastatin) Tablets.

This "Changes Being Effected" supplemental new drug application provides for the addition of post-marketing adverse event information to the Vytorin package insert and patient package insert.

For the package insert, under the **ADVERSE REACTIONS**, *Post-marketing Experience for Ezetimibe* subsection, the words "urticaria, and arthralgia" were added to the list of hypersensitivity reactions.

For the patient package insert, to the third paragraph under the section entitled, "**What are the possible side effects of VYTORIN?**" the words "hives, and joint pain" were added to the list of side effects.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted April 26, 2006)(copy enclosed).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA.* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-687/S-015**." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 796-1295.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Acting Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Eric Colman
7/3/2006 12:31:58 PM
Eric Colman for Mary Parks